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ABSTRACT 21 
 Bordetella bronchiseptica, a Gram-negative bacterium, causes chronic 22 
respiratory-tract infections in a wide variety of mammalian hosts—humans included, 23 
albeit rarely. We recently designed B. pertussis and B. parapertussis experimental 24 
vaccines based on outer-membrane vesicles derived from each pathogen and obtained 25 
protection against the respective infections in mice. Here, we demonstrate that outer-26 
membrane vesicles derived from virulent-phase B. bronchiseptica (OMVBbvir
+
) 27 
protect mice against sublethal infection from different B. bronchiseptica strains, two 28 
isolated from farm animals and one from a human. In all infections, we observed that 29 
the B. bronchiseptica load was significantly decreased in the lungs of the vaccinated 30 
animals: the lung-recovered colony-forming units diminished by at least 4 logs below 31 
those detected in the lungs of non-immunized animals (p<0.001). In the OMVBbvir
+
-32 
immunized mice, we detected IgG-antibody titers against B. bronchiseptica whole-33 
cell lysates along with an immune serum having bacterial-killing activity that both 34 
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recognized B. bronchiseptica lipopolysaccharides and polypeptides such as GroEL 35 
and OMPc and conferred an essential protective capacity against B. bronchiseptica 36 
infection as detected by passive in-vivo–transfer experiments. 37 
 Stimulation of cultured splenocytes from immunized mice by OMVBbvir
+
 38 
resulted in the presence of IL-5, INF-γ, and IL-17 production; indicating that the 39 
vesicles induced a mixed Th2, Th1, and Th17 T-cell–immune-response profile. We 40 
detected by adoptive transfer assay that spleen cells from OMVBbvir
+
-immunized 41 
mice also contributed to the observed protection against B. bronchiseptica infection. 42 
Outer-membrane vesicles from the avirulent-phase B. bronchiseptica and the 43 
resulting induced immune sera were also able to protect mice against B. 44 
bronchiseptica infection 45 
 46 
IMPORTANCE 47 
 Bordetella bronchiseptica, a Gram-negative bacterium, causes chronic 48 
respiratory-tract infections in a wide variety of mammalian hosts—humans included, 49 
albeit rarely. Several vaccines aimed at preventing B. bronchiseptica infection have 50 
been developed and used, but a safe and effective vaccine is still needed. The 51 
significance and relevance of our research lies in the characterization of the outer-52 
membrane vesicles (OMVs) derived from B. bronchiseptica as the source of a new 53 
experimental vaccine. We demonstrated here that our formulation based on OMVs 54 
derived from virulent-phase B. bronchiseptica (OMVBbvir
+
) is effective against the 55 
infection caused by B. bronchiseptica isolates obtained from different hosts: farm 56 
animals and a human. In-vitro and in-vivo characterization of humoral and cellular 57 
immune responses induced by the OMVBbvir
+
 vaccine enabled a better understanding 58 
of the mechanism of protection necessary to control B. bronchiseptica infection. Here 59 
we also demonstrated that OMVs derived from B. bronchiseptica in the avirulent 60 
phase and the corresponding induced humoral immune response are also able to 61 
protect mice from B. bronchiseptica infection. This realization provides the basis for 62 
novel vaccine developments against not only the acute stages of the disease but also in 63 
stages of disease or infectious cycle where avirulence factors could play a role. 64 
 65 
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Introduction 69 
Bordetella bronchiseptica is a Gram-negative bacterium that causes respiratory 70 
diseases in a variety of mammalian hosts [1]. Though this pathogen rarely infects 71 
humans, certain reports have indicated that B. bronchiseptica can infect immune-72 
compromised patients or those with underlying respiratory diseases [2-4]. The 73 
respiratory infections caused by this zoonotic pathogen could also become chronic, 74 
though exhibiting few or no symptoms [5, 6]. The persistence of B. bronchiseptica in 75 
hosts seems to be facilitated through a modification of the expression of bacterial 76 
constituents mainly controlled by a two-component regulatory system encoded by the 77 
bvgAS locus [7, 8]. This system senses signals from the external environments, 78 
regulates the expression of hundreds of genes, and controls different phenotypic 79 
phases [9]. 80 
The prophylaxis of diseases caused by B. bronchiseptica is achieved through 81 
vaccination, but to date no satisfactory vaccine to confer protection in animals against 82 
the acute or chronic infection caused by B. bronchiseptica has been developed. Some 83 
of the current vaccines are composed of either killed wild-type bacterial strains 84 
(administered parentally) or live attenuated strains (administered intranasally) [10, 85 
11]. Most of the vaccines containing the killed bacteria induce high serum antibody 86 
titers but do not always provide an effective protection against infection [10]. The data 87 
on the safety and efficacy of live attenuated vaccines are scarce. Moreover, this kind 88 
of vaccine is not well accepted because the strains included in the vaccines may revert 89 
to full or partial virulence since the basis of the original attenuation is still unknown. 90 
As to the acellular B. bronchiseptica vaccines, one is composed of the immunogenic 91 
Bordetella colonization factor-A protein while others contain pertactin (PRN), the 92 
outer-membrane protein that is a highly immunogenic virulence factor [12-15]. 93 
Although these vaccines appear to resolve mainly the issue related to adverse side 94 
reactions, no conclusive evidence has been garnered to support their immunogenicity 95 
[13, 16]. Therefore, the identification of appropriate bacterial components for the 96 
development of a new vaccine is still needed. In this search, the characteristic 97 
constituents of the avirulent phase could be included in such an evaluation since this 98 
phase seems to be involved in the infectious process [6, 8, 17]. 99 
 In the work reported here, we investigated whether a vaccine based on OMVs 100 
derived from B. bronchiseptica in either the virulent or the avirulent phenotypic phase 101 
would be able to generate a protective immunity against an infection caused by B. 102 
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bronchiseptica. Vaccines based on OMVs against B. pertussis or B. parapertussis 103 
infections have recently been developed by our group [18-22]. The administration of 104 
OMV-based vaccines confers a complete protection against B. pertussis or B. 105 
parapertussis in mice. The protection against B. pertussis is long lasting and is 106 
mediated by both antibodies and CD4
+
 T cells [20]. We have made the interesting 107 
observation that the protective capacity of OMVs obtained from a B. pertussis strain 108 
that expressed the avirulent phenotype was lower than that of the OMVs from 109 
virulent-phase B. pertussis, but the two were nevertheless protective in the mouse 110 
model used [23]. 111 
 These results in combination permit the hypothesis that OMVs derived from 112 
B. bronchiseptica from either the virulent or the avirulent phase could constitute a 113 
suitable candidate for a vaccine against bordetellosis. In fact, the findings described 114 
here support this hypothesis since the protection experiments performed in the murine 115 
intranasal-challenge model demonstrated that the OMV-vaccine derived from virulent 116 
B. bronchiseptica was able to effect a significant decrease in the lung colonization of 117 
different B. bronchiseptica strains obtained from different hosts—i. e., farm animals 118 
or a human. Furthermore, by performing in-vitro and in-vivo experiments, we detected 119 
that both a humoral response possessing killing capacity and immune splenic cells 120 
contributed to the protection induced by the OMVBbvir
+
-vaccines. Moreover, we 121 
have also observed that protective capacity could be induced with a vaccine 122 
formulated from OMVs obtained from B. bronchiseptica in the avirulent phase. 123 
 124 
MATERIALS AND METHODS  125 
Bacterial strains and growth conditions 126 
 Bordetella bronchiseptica strain 9.73 (isolated from a rabbit) [24] and the 127 
mutant derivative strain defective in expression of the BvgA protein (blocked in 128 
avirulent phase) [25] were used throughout this study. Bordetella bronchiseptica 129 
strains were grown on Bordet Gengou agar medium (Difco, Houston TX, USA) 130 
supplemented with 10% (v/v) defibrinated sheep blood (blood was from Laboratorio 131 
Argentino S.A.). For challenge in the animal experiments, the strains from rabbits B. 132 
bronchiseptica 9.73 and B. bronchiseptica RB50 (BbraRB50, kindly provided by Dr. 133 
Peggy Cotter of the University of North Carolina) and B. bronchiseptica AR705 134 
(BbhuAR705, an Argentine clinical isolate obtained from a pediatric patient with cystic 135 
fibrosis) were also used. 136 
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 137 
Isolation of outer-membrane vesicles (OMVs) 138 
 To obtain OMVs from the bacterial cells, we used the method previously 139 
described by us [18, 22, 26]. The procedure stated in brief: Culture samples from the 140 
decelerating growth phase of the bacteria were centrifuged at 10,000 x g for 20 min at 141 
4 ºC and the pellet obtained resuspended in 20 mM Tris-HCl, 2 mM EDTA, pH 8.5 142 
(TE Buffer). Of the resulting pellet, approximately 1 g (wet weight) was resuspended 143 
in 5 ml of the TE Buffer. OMV release was promoted by sonication in ice-water; the 144 
cells were then removed by centrifugation at 10,000 x g and the OMV supernatant 145 
concentrated by ultracentrifugation at 40,000 x g for 3 h. The OMVs thus obtained 146 
were stored at 4 °C. Thereafter the OMVs were examined by electron microscopy 147 
after negative staining [22]. 148 
 149 
Protein assay 150 
 Protein content was estimated by the Bradford method with BSA as a standard 151 
[27]. 152 
 153 
One-dimensional electrophoresis and immunoblotting 154 
 OMV proteins were separated by sodium-dodecyl-sulfate–polyacrylamide-gel 155 
electrophoresis (SDS-PAGE), transferred onto polyvinylidene difluoride (Immobilon 156 
P, Millipore USA) and probed with either a polyclonal anti(adenylate-cyclase 157 
hemolysin) [anti(AC-Hly)] antibody (1:300), an anti-PRN antibody (1:500), an anti-158 
fimbriae (-FIM) antibody (1:500), an anti-flagellin (-FLA; 1:2,000) antibody, or anti-159 
GroEL, an antibody against a protein analogous to the E. coli chaperonin GroEL 160 
(1:5,000) followed by incubation with anti(mouse IgG) conjugated with alkaline 161 
phosphatase at a 1:1,000 dilution. Nitroblue tetrazolium and 5-bromo-4-chloro-3-162 
indolyl-phosphate were used as the phosphatase substrates according to the 163 
manufacturer's protocol (Biodynamics SRL Buenos Aires Argentina). Some of the 164 
proteins present in the vesicles were identified by mass spectrometry after the initial 165 
separation by one-dimensional electrophoresis, as previously described [28, 29]. 166 
 Bordetella bronchiseptica–lipopolysaccharide (LPS) electrophoresis was 167 
performed at room temperature and constant voltage. The LPS were visualized by the 168 
BioRad silver-staining technique. 169 
 170 
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Formulation of vaccines 171 
 To use the OMVs as acellular vaccines, the vesicle preparations were 172 
detoxified by mixing with aqueous formaldehyde (0.37% [v/v] and incubating at 37 173 
°C overnight, and aluminum hydroxide (0.2 mg/ml) was then added as an adjuvant. 174 
 To prepare whole-cell vaccine (WCVBbvir
+
), a suspension containing 2 x 10
10
 175 
colony-forming units (CFUs)/ml of heat-killed (56 °C for 20 min) B. bronchiseptica 176 
9.73 were detoxified in the same manner and were then mixed with aluminum 177 
hydroxide (0.2 mg/ml) as an adjuvant. 178 
 179 
Expression of inflammatory markers upon systemic delivery of OMVs 180 
 In order to assess the proinflammatory capacity of the OMV-based vaccine 181 
formulation, mouse-blood samples were collected 4 h after each immunization by 182 
submandibular bleeding. Serum interleukin-6 (IL-6) was measured by enzyme-linked 183 
immunosorbent assay (ELISA) with the kit BD OptiEIA (BD Biosciences, CA USA) 184 
according to the manufacturer's instructions. 185 
 186 
Active immunization and intranasal challenge 187 
 Four-week-old female BALB/c mice obtained from Biol SAIC, Argentina 188 
were used for all assays. As described previously [29], the immunization protocols 189 
comprised a two-dose schedule with the formulations described above over a period 190 
of 2 weeks. Two weeks after the second immunization, mice were subjected to a nasal 191 
challenge with a sublethal dose (10
5–106 CFUs in 40 µl) of B. bronchiseptica strain. 192 
The lungs of the challenged mice were excised and collected for bacterial counts at 7 193 
days after the challenge. The number of CFUs was determined as previously 194 
described [29]. At least three biological replicates were performed. 195 
 196 
ELISA 197 
 Plates were coated with sonicated B. bronchiseptica (whole-cell lysates) in 0.5 198 
M carbonate buffer, pH 9.5 in an overnight incubation at 4 ºC and then blocked with 199 
3% (v/v) skimmed milk in blocking buffer (2 h at 37 ºC) before incubation with 200 
serially diluted mouse-serum samples (1 h at 37 ºC). The bound IgG was detected 201 
after a 2-h incubation with horseradish-peroxidase– (HRP)-conjugated goat anti-202 
(mouse IgG) at a titer of 1:20,000 (Thermo Fisher Scientific, Buenos Aires 203 
Argentina). For measuring IgG isotypes, detection of bound antibody was determined 204 
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with HRP-labeled subclass-specific anti-(mouse IgG1) at 1:8,000 or IgG2a (1:1,000; 205 
Sigma Aldrich, USA). As substrate 1.0 mg/ ml o-phenylendiamine (OPD, Bio Basic 206 
Canada Inc) in 0.1 M citrate-phosphate buffer, pH 5.0 containing 0.1% hydrogen 207 
peroxide was used. For measuring IgG isotypes, the detection of bound antibody was 208 
determined with the peroxidase bound to subclass-specific anti–mouse-IgG1 (1:8,000) 209 
or -IgG2a (1:1,000; Sigma, Aldrich). Optical densities (ODs) were measured with 210 
Titertek Multiskan Model 340 microplate reader (ICN, USA) at 492 nm, and the OD 211 
was plotted as a function of the log of the (serum dilution)
–1
. The inflection point of 212 
the curve was determined by the GraphPadPrims® software. Titers were defined as 213 
the reciprocal of the serum dilution giving an OD corresponding to the inflection 214 
point of the curve. 215 
 216 
Bactericidal Assay 217 
 The bactericidal activity of the sera collected from mice two weeks after 218 
immunization with the OMVBbvir
+
 vaccine (i. e., the immune sera) and from non-219 
immunized mice (i. e., the naïve sera) were tested in vitro. Both, immune and naïve 220 
sera inactivated by heat, and phosphate-buffered saline (PBS) were use as controls. 221 
Virulent B. bronchiseptica 9.73 were grown on Bordet Gengou agar medium and 222 
diluted to 1 x 10
5
 CFUs/ml in PBS containing MgCl2 0.05 M, CaCl2 0.15 mM. Forty-223 
five µl of serum or PBS were mixed with 5 µl of a suspension containing 500 CFUs 224 
of the bacteria. After 1 h of incubation at 37 °C, serial dilutions of the samples were 225 
spread on Bordet Gengou agar plates and incubated for 48–72 h to determine the 226 
CFUs. At least three biological replicates were performed. 227 
 228 
Analysis of cellular response elicited by vaccination 229 
 The cellular response was analyzed as previously described [20]. The 230 
procedure stated in brief: Spleen cells from mice immunized with the OMV-based 231 
vaccine were harvested 8 weeks after the last immunization and seeded in 48-well 232 
culture plates at 10
6
 per well in a volume of 500 µl of RPMI 1640 cell-culture 233 
medium supplemented with 10% (v/v) fetal-bovine serum (Invitrogen, Buenos Aires 234 
Argentina) containing 100 IU/ml penicillin and 100 µg/ml streptomycin. All the 235 
spleen cells were either stimulated with OMVs derived from B. bronchiseptica (5 236 
µg/ml) or exposed to medium alone. Supernatants were removed after 72 h of 237 
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incubation at 37 °C in an atmosphere of 5% CO2 and the production of interferon-γ 238 
(IFN-γ), IL-17, and IL-5 determined by ELISA (BD Biosciences, CA USA), 239 
according to the conditions specified by the manufacturer. 240 
 241 
Adoptive transfer 242 
 Pooled serum (100 µl) or spleen cells (5 x 10
6
) from non-immunized mice or 243 
from mice immunized with the OMV-based vaccine two weeks previously were 244 
transferred intraperitoneally to female BALB/c mice. Twenty-four hours thereafter the 245 
mice were infected with a sublethal dose (10
5–106 CFUs 40 in µl) of B. 246 
bronchiseptica 9.73 and the subsequent protection assessed by determining the CFU 247 
counts in the mouse lungs 7 days after the challenge. 248 
In order to evaluate the contribution of CD4
+
 T cells in the protection, adoptive 249 
transfer assays were also performed using spleen cells obtained from animals 250 
immunized with OMVBbvir+ and depleted in CD4
+
 T cells. Depletion of CD4
+
 T 251 
cells in vaccinated mice was performed by intraperitoneal injection with the 252 
monoclonal antibody from GK1.5 hybridoma (61.2 mg/ml) specific for CD4. The 253 
dosing schedule consisted in the administration to the donor animals of 200 μl of the 254 
antibody the day before spleens were collected for the passive immunization protocol. 255 
After spleen cells transfer, receptor animals received 2 doses of anti-CD4 antibody to 256 
ensure the depletion. Depletion of CD4+ T cells was confirmed by a reduction of at 257 
least 95% of the lymphocyte CD4 (+) population in blood and spleen by flow 258 
cytometry. Donor mice treated with control isotype (IgG2bk) were included in the 259 
assays for comparison purposes. 260 
 261 
Statistical analysis 262 
 The data were evaluated statistically by one-way analysis of variance 263 
(ANOVA) followed by the Tukey test post-hoc (via the GraphPad Prism® software). 264 
Differences were considered significant at a p <0.05. 265 
 266 
RESULTS 267 
Isolation and characterization of the OMVs obtained from B. bronchiseptica 9.73 268 
grown in the virulent phase 269 
 The OMV samples obtained from B. bronchiseptica 9.73 grown in the virulent 270 
phase (OMVBbvir
+
) were negatively stained and examined by electron microscopy 271 
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(Fig. 1, Panel A). The procedure was repeated at least 8 times, and in all the samples 272 
the size range (at dimensions of 50–150 nm) was both consistent from batch to batch 273 
and similar to that previously described for OMV preparations derived from B. 274 
pertussis [22]. To further characterize these OMVBbvir
+
, one-dimensional 275 
electrophoresis (Fig. 1, Panel B) and immunoblotting (Fig. 1, Panel C) were 276 
performed. By this assay we could detect that the OMVBbvir
+
 isolates contained AC-277 
Hly, PRN, and FIM2 (Fig. 1, Panel C). 278 
 279 
IL-6 levels after immunization 280 
 Usually after the systemic immunization of an animal, a rise in 281 
proinflammatory cytokines can be detected. The levels are related to the 282 
proinflammatory capability of the formulation employed. IL-6 is among the 283 
proinflammatory cytokines usually chosen as an indicator of this activity [30]. In our 284 
experiments, the OMVBbvir
+
-containing formulations induced levels of IL-6 (425.54 285 
± 34.00 pg/ml) that were significantly lower than those detected for the B. 286 
bronchiseptica whole-cell vaccine (53,673.08 ± 5,987.44 pg/ml). 287 
 288 
Protection against intranasal B. bronchiseptica challenge after vaccination with 289 
OMVBbvir
+
 290 
 To evaluate the protective capability of the OMVBbvir
+
 vaccine against B. 291 
bronchiseptica challenge, we used the murine model of intranasal infection. The 292 
CFUs recovered from the lungs of the OMVBbvir
+
-immunized mice were compared 293 
with those assayed in mice immunized with the B. bronchiseptica 9.73 whole-cell 294 
vaccine prepared in our laboratory from wild-type bacteria in the virulent phase 295 
(WCVBbvir
+
, Fig. 2, Panel A). Significant differences in the lung bacterial counts 296 
between the OMVBbvir
+
-immunized animals and non-immunized mice were obtained 297 
(p <0.001; Fig. 2, Panel A). The number of colonies recovered from the lungs of the 298 
OMVBbvir
+
-immunized mice at day 7 after challenge was at least 4 logs lower than 299 
those detected in the non-immunized animals and similar to those from the 300 
WCVBbvir
+
-immunized mice (Fig. 2, Panel A). 301 
 We next sought to investigate if the protective capability induced by the 302 
OMVBbvir
+
 vaccine extended to strains other than B. bronchiseptica 9.73. To that 303 
end, we performed in-vivo protection assays using two other strains of B. 304 
bronchiseptica for challenge, one from a farm animal (BbraRB50) and the other 305 
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recovered from a pediatric patient with cystic fibrosis (BbhuAR705). Mice were 306 
accordingly immunized twice with the OMVBbvir
+
 formulation and then challenged 2 307 
weeks after the second immunization with a sublethal dose of each B. bronchiseptica 308 
strain:—i. e., BbraRB50 and BbhuAR705. As a negative control we used non-309 
immunized mice. For both strains used in the bacterial challenge, significant 310 
differences in lung B. bronchiseptica colony-formation counts of more than 4 logs 311 
were obtained between the immunized animals and the negative control group (p 312 
<0.001; Fig. 2, Panel B). 313 
 314 
Characterization of the humoral immune response induced by OMVBbvir
+
 315 
 To characterize the immune response induced by the OMVBbvir
+
 vaccine 316 
derived from B. bronchiseptica 9.73, titers of antibody were quantitatively measured 317 
(Table 1). In comparison with the antibody levels detected in negative-control 318 
animals, higher serum levels of specific IgG were found at 14 days after the OMV 319 
priming (Table 1). Further tests were then conducted to determine the antibody 320 
subtypes. Mice immunized with OMVBbvir
+
 produced high titers of specific IgG1 321 
and IgG2a antibodies. The specific IgG1 titer was higher than that of the specific 322 
IgG2a (IgG1:IgG2a = 2.2; Table 1). Examination of these IgG subclasses indicated 323 
that the mice had responded to the OMVBbvir
+
 vaccination with a mixed Th1/Th2 324 
profile, but with mainly a skewed Th2-type immune response. 325 
 To identify the main immunogenic proteins present in the OMVs, we analyzed 326 
the antibody profile by immune proteomics. This analysis was achieved by examining 327 
the reactivity of sera induced by the OMVBbvir
+
 vaccine against proteins from the 328 
OMV derived from B. bronchiseptica. Fig. 3, Panel A shows protein bands detected in 329 
OMVBbvir
+
 that cross-reacted with sera induced by vaccination with OMV. The 330 
identity of some of those antigens was determined after the selected immunoreactive 331 
bands were excised from the one-dimensional electrophoretic gels and then analyzed 332 
by mass spectrometry. Bands a, and b in Fig. 3, Panel A, for example, were identified 333 
as the GroEL-like protein and the outer-membrane protein OMPc, respectively. The 334 
mass-spectrometric identification of the protein indicated as GroEL in particular was 335 
subsequently confirmed by immunoreactivity with a GroEL-specific antibody (not 336 
shown). 337 
 To investigate the presence of specific antibodies against the LPS in the 338 
OMVBbvir
+
-immune serum, we performed a Western-blot analysis to determine the 339 
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mobility on SDS PAGE of the purified wild-type B. bronchiseptica 9.73 LPS. The 3 340 
expected bands were observed: a diffuse one (the lipid-A–KDO core O antigen) 341 
containing the O antigen (a single sugar polymer consisting of 2,3-dideoxy-di-N-342 
acetylgalactosaminuronic acid) and the two other faster migrating bands—i. e., Band 343 
A (the lipid-A–KDO core) and Band B (lipid-A–KDO) [31]. As anticipated, these 344 
LPS-associated bands were recognized by the immune serum induced by OMVBbvir
+
 345 
vaccination (Fig. 3, Panel B). 346 
 Since the activated components of complement had been previously reported 347 
to mediate—at least in part—the killing of B. bronchiseptica bacteria by direct 348 
bacterial lysis, we next performed a killing assay with immune serum [32]. For this 349 
determination, a suspension of 500 B. bronchiseptica 9.73 bacteria was incubated in 350 
50 µl of 90% (v/v) serum in PBS to ensure that the serum components were not 351 
limiting. This assay revealed that the B. bronchiseptica 9.73 bacteria were sensitive to 352 
the immune sera (to a degree of ca. 50% survival), but resistant to naïve serum (i. e., 353 
with 100% surviving; Fig. 3, Panel C). In control experiments using heat-inactivated 354 
sera we found 100% of bacterial survival for both immune and naïve sera. 355 
 To examine the specific role of antibodies in the control and clearance of B. 356 
bronchiseptica, serum from naïve or immunized animals was adoptively transferred 357 
into naïve animals 24 h before challenge with B. bronchiseptica (5 x 10
5
 CFUs B. 358 
bronchiseptica 9.73). This OMVBbvir
+
-induced serum—collected from the mice 14 359 
days after the second dose—cleared B. bronchiseptica from the mouse lungs by day 7 360 
after the inoculation (at a reduction of 3.5 logs), whereas naïve serum had no 361 
significant effect (Fig. 3, Panel D). 362 
 All the results presented here indicated that the OMVBbvir
+
 vaccine induced a 363 
robust humoral immunity that effected an induced protection against B. 364 
bronchiseptica—at least partially—as a consequence of the killing activity of the 365 
serum. 366 
 367 
Induction of a mixed Th1, Th2, and Th17 immune response by OMVBbvir
+
 368 
vaccination 369 
 To characterize the T-cell profile induced by the OMVBbvir
+
 vaccine, we 370 
determined the levels of IFN-γ, IL-17, and IL-5 (markers of the respective Th1, Th17, 371 
and Th2 immune responses) produced by stimulated spleen-cell cultures (Fig. 4). 372 
Lymphocyte-proliferation assays revealed that OMVBbvir
+
 vaccination effectively 373 
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stimulated lymphocyte proliferation (not shown). Two months after immunization, 374 
higher concentrations of IFN-γ (5,514.48 ± 1,198.51 pg/mL; Fig. 4, Panel A) and IL-375 
17 (8,645.97 ± 1,796.29 pg/mL; Fig. 4, Panel B) were produced by spleen cells from 376 
OMVBbvir
+
-immunized mice than those present in non-immunized mice (Fig. 4). IL-377 
5 was also detected (469.14 ± 67.03 pg/mL) in the supernatants of stimulated 378 
splenocytes from OMVBbvir
+
-immunized mice (Fig. 4, Panel C). All these findings 379 
strongly indicate that OMVBbvir
+
 vaccination induces a mixed Th1-Th17-Th2 380 
spleen-cell profile. 381 
 To investigate the role of OMVBbvir
+
 immune spleen cells in protection, we 382 
injected BALB/c mice i.p. with 5 x 10
6
 intact spleen cells from nonimmunized 383 
animals or from mice that had been immunized with OMVBbvir
+
 vaccine 2 weeks 384 
before. Twenty-four hours later, the mice were infected with 5 x 10
5
 CFUs of B. 385 
bronchiseptica 9.73 and then sacrificed 7 days later to determine the number of CFU 386 
counts in the lungs (Fig. 4, Panel D). The transfer of spleen cells from immunized 387 
animals, but not from the non-immunized mice, resulted in a reduction in bacterial 388 
colonization of approximately 2 logs. To look specifically at the function of CD4
+
 T 389 
cells in the protection against B. bronchiseptica colonization; spleen cells from mice 390 
immunized with OMVBbvir
+
 and treated with anti-CD4 antibody were administered 391 
to naive mice 24 h before challenge with a sublethal dose of B. bronchiseptica. 392 
Depletion of CD4
+
 T cells in the spleen of the donor animals, increased the counts of 393 
bacteria recovered from the lungs of the recipient animals. The bacterial counts 394 
detected in these animals were similar to those found in the lungs of mice that 395 
received the spleen cells of naive animals (Fig. 3 Panel D). 396 
All these results indicate that spleen cell-mediated immunity, and in particular 397 
the CD4
+ 
T cells, plays a role in the protection against B. bronchiseptica induced by 398 
the OMVBbvir
+
 vaccine.  399 
 400 
Protection against intranasal B. bronchiseptica challenge after vaccination with 401 
OMV from B. bronchiseptica blocked in the avirulent phase 402 
 Since the avirulent phase of B. bronchiseptica could be involved in some stage 403 
of the infectious cycle (i.e during the chronic infection), we sought to evaluate 404 
whether an experimental vaccine containing the OMV derived from B. bronchiseptica 405 
9.73 blocked in the avirulent phase (OMVBbvir
–
) was able to confer protection 406 
against B. bronchiseptica infection. To this end, OMVs were obtained from a mutant 407 
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previously constructed in our laboratory that was defective in the two-component 408 
signal-transduction regulatory system BvgA of B. bronchiseptica [25]. The 409 
characterization of OMVBbvir
–
 evidenced no differences from the OMVBbvir
+
 in 410 
their size distribution, as evaluated by electron microscopy (Fig. 5, Panel A); but 411 
certain changes in the electrophoretic profile were detected, even though the major 412 
components were the same as those of the OMVBbvir
+ 
(Fig. 5, Panel B, left lane). The 413 
lack of expression of the main virulence factors and the expression of the flagellin as 414 
an avirulent marker were evidenced upon immunoblotting (Fig. 5, Panel B, right 415 
lanes). After this initial characterization of the OMVs, intranasal B. bronchiseptica 416 
challenges were performed. In those experiments, we analyzed the effect of two 417 
previous administrations of the OMVBbvir
–
 preparation on the subsequent 418 
colonization of the lungs of the experimental mice by the B. bronchiseptica strain 9.73 419 
(≈106 CFUs in 40 µl; Fig. 5, panel C and D). The results were compared with those 420 
obtained for mice that had been preimmunized with the OMVBbvir
+
 vaccine (Fig. 5, 421 
Panel C). PBS-injected mice served as a negative control. Significant differences in 422 
the lung bacterial counts between the immunized animals and the negative control 423 
group were observed (p <0.001; Fig. 5). Of major significance was the observation 424 
that protection against B. bronchiseptica challenge was also achieved at same level by 425 
the OMVBbvir
–
 immunization. The number of CFUs recovered from the lungs at day 426 
7 after challenge likewise dropped by at least 4 orders of magnitude compared to that 427 
of the non-immunized mice (Fig. 5, Panel C). 428 
 For this experimental vaccine, we also evaluated the specific role of induced 429 
antibodies in the control and clearance of B. bronchiseptica. For that purpose, serum 430 
from naïve or immunized animals was adoptively transferred into naïve animals 24 h 431 
before a challenge with B. bronchiseptica (5 x 10
5
 CFUs of B. bronchiseptica 9.73). 432 
As had been detected with the OMVBbvir
+
 vaccine, the OMVBbvir
–
-induced 433 
serum—collected from mice 14 days after the second dose—cleared B. bronchiseptica 434 
(by a reduction of 3.5 logs) from the lungs of the challenged mice by day 7 post-435 
inoculation, whereas the naïve serum had no significant effect (Fig. 5, Panel D). 436 
 The results presented in this final section would clearly indicate that both the 437 
OMVBbvir
–
 vaccine and its induced humoral immunity possessed the capability of 438 
protecting mice against an infection caused by B. bronchiseptica. 439 
 440 
DISCUSSION 441 
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 In this report we describe the development and evaluation of OMVs obtained 442 
from B. bronchiseptica as vaccines against lung colonization. As we had previously 443 
observed in the OMVs derived from B. pertussis, the sizes of the OMVs from B. 444 
bronchiseptica 9.73 (at dimensions of 50–150 nm) were consistent from batch to 445 
batch. Furthermore, the well known principal B. bronchiseptica surface immunogens 446 
such as PRN, AC-Hly, and FIM were also detected in the OMVs through 447 
immunoblotting. The OMVBbvir
+
 thus characterized were then used in the murine 448 
model to examine their safety and protective capability. In the first experiments 449 
described, we performed comparisons with a whole-cell vaccine prepared in our 450 
laboratory since a previous report had indicated that the same type of formulation in 451 
dogs reduced the disease burden and the lesions in the vaccinated animals relative to 452 
those of infected naïve controls [10]. We observed that two doses of our experimental 453 
OMVBbvir
+
 vaccine administered 2 weeks before B. bronchiseptica challenge fully 454 
protected the BALB/c mice against the colonization of different B. bronchiseptica 455 
strains obtained from diverse hosts—two representative ones being shown: a farm 456 
animal and a human). As to the safety of these preparations, in comparison with the 457 
whole-cell vaccine, we observed only a minimal rise in the levels of the 458 
proinflammatory IL-6 in serum just after OMV vaccination. These results would 459 
position the OMV-based vaccines above the classic cellular preparations; as 460 
OMVBbvir
+
 induces equal levels of protection, but along with adequate levels of 461 
safety. Another significant and relevant result detected with our experimental vaccine 462 
was that ability to induce protection against different isolates of B. bronchiseptica 463 
obtained from diverse hosts. This result becomes especially pertinent upon 464 
consideration of the diversity of genotypes already reported for B. bronchiseptica [33, 465 
34] since this finding would indicate that the formulation of a specific OMV-based 466 
vaccine for each specific isolate would be unnecessary. 467 
 In the present work, we also detected that the antibody titers of OMVBbvir
+
-468 
vaccinated mice were higher on day 14 after the second dose and before B. 469 
bronchiseptica challenge than those of the non-immunized control group. Moreover, 470 
this OMVBbvir
+
-vaccine–induced immune serum recognized a group of antigens that 471 
included OMPc and the GroEL-like protein along with LPS. That the OMPc and 472 
GroEL-like protein had been previously detected in mice immunized with OMV 473 
derived from B. pertussis [23] was of interest to us. As discussed in a previous 474 
publication, both proteins in Bordetella and other microorganisms have been 475 
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described as promising vaccine targets [35, 36]. By immunoblotting assays we also 476 
detected that the OMVBbvir
+
 was able to induce antibodies against these LPS, an 477 
immunogenic bacterial component with proven protective capability [37]. Based on 478 
the detection of these protection-inducing immunogens, we next sought to investigate 479 
if the OMVBbvir
+
 vaccine-induced antibodies alone were sufficient to confer 480 
protection against B. bronchiseptica. The passive-transfer assays we therefore 481 
performed demonstrated that the vaccine-induced serum reduced the number of viable 482 
bacteria in the lungs by about 4 logs. This protective role of the antibodies was in 483 
accordance with previous results reported by other authors [38]. In fact, protection 484 
against B. bronchiseptica infection had been evidenced with antibodies induced by 485 
either infection or vaccination [38] through mechanisms that appeared to be different: 486 
whereas the immunity induced by previous infection offered significant protection 487 
even in the absence of complement or the induction of the monocyte IgG receptors 488 
-489 
[38]. 490 
 In addition, we found that CD4
+ 
T cells also contributed to the protection 491 
exhibited by the OMVBbvir
+
-based vaccine. The protection against B. bronchiseptica 492 
infection induced by the OMV-based vaccine seems to involve a dual mechanism 493 
involving both a humoral and a cellular immune response as was evidenced by 494 
adoptive transfer experiments. 495 
 Based on our previous results with OMVs derived from B. pertussis in the 496 
avirulent phase, [23] and taking into account the potential role of that phase in the 497 
induction of B. bronchiseptica the infection process (i.e chronic infection), we 498 
decided to evaluate if the OMVs derived from B. bronchiseptica blocked in the 499 
avirulent phase (OMVBbvir
–
) were also able to induce protection. The OMVBbvir
–
 500 
formulation indeed proved to be protective, as judged by the significant decrease of 4 501 
logs observed in the lung bacterial counts between avirulent OMVBbvir
–
-immunized 502 
mice and the non-immunized control group (p <0.001; Fig. 5, panels C and D). The 503 
detected flagella of B. bronchiseptica in the OMVBbvir
– 
preparation probably 504 
contributes to the protective capacity of the OMVBvir
-
 formulation since it has been 505 
described as a potent proinflammatory factor that induces chemokines, cytokines and 506 
expression of the host defense gene [39]. In addition, it was demonstrated that B. 507 
bronchiseptica flagellin is able to effectively signal through both human and mouse 508 
the Toll-like receptor 5 [39]. The protective effect is elicited by non-replicative 509 
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avirulent components that have thus far not been reported as capable of conferring 510 
protection against B. bronchiseptica. To our knowledge, the only report regarding a 511 
vaccine with avirulent B. bronchiseptica, was done in dogs with a live, intact avirulent 512 
strain [40]. Moreover, the authors demonstrated that the vaccinated dogs were 513 
protected against colonization by as early as 48 h after immunization [40]. 514 
 Considered all together, the results presented here provide clear evidence that 515 
the OMVs derived from B. bronchiseptica exhibit a high level of protection against B. 516 
bronchiseptica that is not dependent on bacterial virulence-factor expression. 517 
Moreover, we further demonstrate that the protection induced by these OMVBb-based 518 
vaccines is mediated mainly by antibodies but also by CD4+T cells. 519 
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 674 
Table 1. Serum IgG and isotypes antibodies titers. 675 
 Total IgG   IgG2a IgG1 IgG1:IgG2a 
OMVBbvir
+
 immunized 259.6 ± 32.4 250.2 ± 71.9 558.7 ± 124.3 2.2 
Non-immunized 9.3 ND 11.3  
 676 
 LEGENDS TO THE FIGURES 677 
Fig. 1. Panel A: Transmission-electron-microscopy image of the negatively stained 678 
preparations obtained from B. bronchiseptica 9.73 in the virulent phase (OMVBbvir
+
; 679 
scale bar: 200 nm). Panel B: Analysis of OMVBbvir
+
 by 12.5% (w/v) SDS-PAGE. 680 
The bands were visualized by staining with Coomassie brilliant blue R-250. 681 
Molecular weights in kDa are indicated on the left. Panel C: Immunoblots of 682 
OMVBbvir
+
 and purified proteins indicating the bands binding to anti-AC-Hly–, anti-683 
PRN–, and anti-FIM2–specific polyclonal mouse antibodies. In the figure, the sources 684 
of the samples are indicated above the panels. 685 
 686 
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Fig. 2.  Effect of (i.p.) immunization with active OMVBbvir
+
 in the mouse-intranasal-687 
challenge model. WCVBbvir
+
 was used as a positive control. Panel A: B. 688 
bronchiseptica 9.73 was used as challenge bacteria (5 x 10
5
 CFUs in 40 µl). Panel B: 689 
Rabbit B. bronchiseptica RB50 and the human clinical isolate B. bronchiseptica 690 
AR705 were also used as challenge bacteria (5 x 10
5
 CFUs in 40 µl). In all instances 691 
three biological replicates were performed, with the results from a representative one 692 
being presented. Results depicted are the means of four mice per group at 7 days after 693 
challenge. The line indicates the lower limit of detection. In both panels, the number 694 
of bacteria recovered from the mouse lungs, expressed as the log10means ± SEM 695 
(error bars) of the CFUs per lungs, is plotted on the ordinates for the samples from the 696 
lungs of the experimental groups indicated on the abscissas. The bronchiseptica 697 
strains used for the challenges are depicted above the panels. The asterisks (*) 698 
indicate significant differences at a p <0.001. 699 
 700 
Fig. 3. Panel A: Analysis of OMVBbvir
+
 antigenic reactivity by 12.5% (w/v) SDS-701 
PAGE visualized by staining with Coomassie Brilliant Blue (Lane 1). Molecular 702 
weights in kDa are indicated on the left. Immunoblots (Lane 2) with the OMVBbvir
+
-703 
protein sample were probed against polyclonal antiserum obtained from mice 704 
immunized with OMVBbvir
+
. Bands a and b were identified as GroEL and OMPc 705 
respectively. Panel B: Analysis of purified B. bronchiseptica LPS by 15% (w/v) SDS-706 
PAGE (Lane 1) and by immunoblotting with the polyclonal antiserum obtained from 707 
mice immunized with OMVBbvir+ (Lane 2). The arrows indicate the locations of the 708 
O antigen and the bands A and B that were recognized by the antiserum used in 709 
immunoblotting in Lane 2. Panel C: In-vitro–killing assay of B. bronchiseptica with 710 
immune sera derived from OMVBbvir
+
-vaccinated animals and from non-immunized 711 
mice. Three biological replicates were performed, with the results from a 712 
representative one being presented. The asterisks (*) indicate significant differences at 713 
a p <0.05. In the panel, the percent survival of the bacteria is plotted on the ordinate 714 
for each of the sera indicated on the abscissa. Panel D: Effect of passive 715 
immunization with sera collected from OMVBbvir
+
 immunized mice. B. 716 
bronchiseptica 9.73 was used as the challenge bacterium (5 x 10
5
 CFUs in 40 µl). 717 
Three biological replicates were performed, with the results from a representative one 718 
being presented. The data are the mean values from four mice per group at 7 days 719 
after challenge. The line indicates the lower limit of detection. In the panel, the 720 
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number of bacteria recovered from the mouse lungs, expressed as the log10(means ± 721 
SEM [error bars]) of the CFUs per lungs, is plotted on the ordinate for each of the 722 
experimental groups on the abscissas. The asterisks (*) indicate significant 723 
differences at a p <0.001. 724 
 725 
Fig. 4. Panels A–C: Cytokine production by splenocytes from immunized mice. 726 
BALB/c mice were immunized with two doses of OMVBbvir
+
 or left non-727 
immunized. Two months after the final immunization, the mice were sacrificed and 728 
their cultured spleen cells stimulated with OMVBbvir
+
 or simply incubated in the 729 
culture medium (negative control). After 72 h, the concentrations of IFN-γ (Panel A), 730 
IL-17 (Panel B), and IL-5 (Panel C) were determined by ELISA in the culture 731 
supernatants. The results are expressed as the mean values (± the standard error) of 732 
three experiments with 4 mice per group. Significant differences were analyzed for 733 
each cytokine between non-immunized and immunized mice (p ≤0.01, Panel A) or p 734 
<0.001 (panels B and C). In each of the three panels, the concentration of the cytokine 735 
indicated on the ordinate in -pg.ml
–1
 that was assayed in the culture supernatant is 736 
plotted for the two experimental conditions—exposure to medium or vesicles—737 
designated on the abscissa.  Panel D: Effect of passive immunization with spleen cells 738 
collected from OMVBbvir
+
 immunized mice with or without depletion of CD4
+
 T 739 
cells. Donor animals were i.p. injected with anti-CD4 antibody or the corresponding 740 
isotype control 24 h before the spleens were collected. After the i.p. injection of 741 
spleen cells from OMVBbvir
+
-immunized or non-immunized mice, as indicated on 742 
the abscissa, the recipient mice were challenged with B. bronchiseptica 9.73 (5 x 10
5
 743 
CFUs in 40 µl). Three biological replicates were performed, with the results from a 744 
representative one being presented. The data represent the means of four mice per 745 
group at 7 days after challenge. The line indicates the lower limit of detection. In the 746 
panel, the number of bacteria recovered from the mouse lungs, expressed as the 747 
log10means ± SEM (error bars) of the CFUs per lungs, is plotted on the ordinate for 748 
the samples from the lungs of the mice receiving the spleen cells from the source 749 
indicated on the abscissa. In all four panels, the white bars indicate spleen cells from 750 
non-immunized mice and the black bars those from immunized mice. The asterisks 751 
(*) indicate significant differences at a p <0.001.  752 
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Fig. 5. Panel A: transmission-electron-microscopy image of negatively stained OMVs 754 
obtained from B. bronchiseptica 9.73 in the avirulent phase (OMVBbvir
–
; scale bar: 755 
200 nm). Panel B: Analysis of OMVBbvir
–
 by 12.5% (w/v) SDS-PAGE with 756 
visualization by Coomassie Brilliant Blue. Molecular weights are indicated (on the 757 
left side). On the right side, immunoblots of OMVBbvir
–
 and the purified 758 
recombinant proteins AC-Hly, PRN, FLA, and FIM2, as detected by the respective 759 
specific polyclonal mouse antibodies. Panel C: Effect of active (i.p.) immunization 760 
with OMVBbvir
–
 in the mouse intranasal challenge model. Panel D: Effect of passive 761 
immunization with sera collected from OMVBbvir
–
-immunized mice. For panels C 762 
and D, B. bronchiseptica 9.73 was used as the challenge bacterium (1 x 10
6
 CFUs in 763 
40 µl). Three biological replicates were performed, with the results from a 764 
representative one being presented. The data represent the means of four mice per 765 
group at 7 days after challenge. The line indicates the lower limit of detection. In the 766 
panels, the number of bacteria recovered from the mouse lungs, expressed as the 767 
log10means ± SEM (error bars) of CFUs per lungs, is plotted on the ordinates for the 768 
lung samples from the mice receiving the immunogen—in the form of vesicles (Panel 769 
C) or serum (Panel D)—indicated on the abscissas. The asterisks (*) indicate 770 
significant differences at a p <0.001. 771 
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